Halberd Corporation, a biotech company, develops treatments for neurodegenerative diseases. It offers treatments for post traumatic stress disorder/chronic traumatic encephalopathy, Alzheimer's and Parkinson's disease, cancer, blood-borne, and cerebrospinal fluid related diseases. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.
Stock data | 2023 | Change |
---|---|---|
Price | $0.0053 | N/A |
Market Cap | $2.72M | N/A |
Shares Outstanding | 512.87M | 0.09% |
Employees | 0 | N/A |
Shareholder Equity | -926.37K | 27.26% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 997.50 | N/A |
P/B Ratio | -2.93 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.4902 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $2.73K | N/A |
Earnings | -$454.07K | N/A |
Gross Margin | 0.4844 | N/A |
Operating Margin | -164.11 | N/A |
Net income margin | -166.63 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $12.28K | N/A |
Cash on Hand | $6.92K | N/A |
Debt to Equity | -1.0133 | -1.00% |
Current Ratio | 0.0111 | -47.34% |